Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 2/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.34 |
| ▸ | MTOR | P42345 | 2/20 | 0.34 |
| ▸ | MAP3K14 | Q99558 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21096808 | 0.87 | MAP3K14 (0.46) | ADORA2AADORA1PIK3CAMTORMAP3K14 | |
| SCHEMBL21097146 | 0.87 | ADORA2A (0.37) | ADORA2AADORA1PIK3CAMTORMAP3K14 | |
| SCHEMBL21096679 | 0.86 | MAP3K14 (0.39) | ADORA2AADORA1PIK3CAMTORMAP3K14 | |
| SCHEMBL21096678 | 0.83 | MAP3K14 (0.44) | ADORA2AADORA1PIK3CAMTORMAP3K14 | |
| SCHEMBL21097167 | 0.81 | MAP3K14 (0.40) | ADORA2AADORA1MTORMAP3K14 | |
| SCHEMBL21096520 | 0.81 | MAP3K14 (0.55) | MAP3K14 | |
| SCHEMBL16205749 | 0.80 | MTOR (0.32) | MTORMAP3K14 | |
| SCHEMBL21096807 | 0.80 | PIK3CA (0.40) | ADORA2APIK3CAMAP3K14 | |
| SCHEMBL21096684 | 0.79 | PIK3CA (0.39) | ADORA2APIK3CAMAP3K14 | |
| SCHEMBL16205608 | 0.78 | MTOR (0.37) | PIK3CAMTORMAP3K14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10323045-B2 | Thienopyrimidine derivatives as NIK inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2019-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10323045-B2 | Thienopyrimidine derivatives as NIK inhibitors | MAP3K14, MAP3K15, MAP3K12 | ADORA2A 4258/4885ADORA1 4195/4885PIK3CA 164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.